local_hospital

Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola

Address
lock Available on a paid plan

Gastroenterology and Inflammatory Bowel Disease

At Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola in Rome, clinical research in digestive system diseases focuses on ulcerative colitis, Crohn's disease, and other inflammatory conditions affecting the gut. These studies are designed to test new treatments and better understand how to achieve and maintain remission in chronic intestinal disease.

  • Testing novel therapies for ulcerative colitis
  • Evaluating treatment options for Crohn's disease
  • Studying approaches to improve clinical remission and long-term disease control

The site also explores related gastrointestinal conditions such as eosinophilic gastritis, reflecting a broader interest in improving care for patients with difficult-to-treat digestive disorders.

Oncology and Precision Cancer Care

Research in neoplasms is a major focus, with trials covering breast cancer, colorectal cancer, lung cancer, melanoma, and head and neck cancer. Many of these studies aim to improve how cancers are treated after surgery, in advanced disease, or when standard options are no longer effective.

  • Evaluating new treatment strategies for advanced solid tumors
  • Studying therapies for breast cancer and triple-negative breast cancer
  • Assessing options for colorectal cancer and metastatic disease
  • Testing treatment effectiveness in non-small cell lung cancer, small cell lung cancer, and melanoma

These trials are largely focused on improving survival, controlling disease progression, and identifying more effective personalized cancer treatments.

Neurology and Alzheimer’s Disease

The site supports clinical trials in nervous system diseases, especially Alzheimer's disease and early symptomatic Alzheimer’s disease. This research is aimed at understanding whether new therapies can slow cognitive decline and support patients in the earliest stages of memory loss and dementia.

  • Testing potential treatments for early Alzheimer’s disease
  • Evaluating safety and long-term tolerability of new neurological therapies
  • Studying whether treatment can slow clinical progression and preserve function

These studies reflect a strong interest in finding better ways to diagnose and manage progressive brain disorders before they advance further.

Cardiovascular and Metabolic Research

Clinical trials in cardiovascular diseases, nutritional and metabolic diseases, and related metabolism and immune system phenomena include studies in type 2 diabetes, acute myocardial infarction, heart failure due to ATTR amyloidosis, chronic kidney disease, and broader cardiometabolic risk reduction. The goal is to improve outcomes in patients with common and high-risk chronic illnesses.

  • Testing therapies to reduce major adverse cardiovascular events
  • Studying treatment effects in type 2 diabetes and cardiovascular autonomic neuropathy
  • Evaluating options for chronic kidney disease progression
  • Exploring new care strategies for ATTR amyloid cardiomyopathy

Research here often connects heart, kidney, and metabolic health, showing a broad interest in preventing complications across multiple organ systems.

Respiratory, Skin, and Ophthalmology Studies

Additional work spans respiratory tract diseases, skin and connective tissue diseases, and eye diseases. These trials involve conditions such as asthma, chronic spontaneous urticaria, and neovascular age-related macular degeneration, with a focus on improving symptom control and quality of life.

  • Assessing new treatments for asthma
  • Studying therapies for chronic spontaneous urticaria
  • Evaluating approaches for neovascular age-related macular degeneration
  • Supporting research into immune-related skin and allergy conditions

These studies broaden the research portfolio at the Rome site by addressing chronic conditions that affect breathing, skin health, and vision.

Site Overview

assignment
42
connected trials
corporate_fare
29
sponsors
science
98
IMPs

Activity Indicator

Last 6 months

7
Trials started
0% vs previous period.
7
Trials started 6–12 months ago
42
Total trials linked
Highly Active
trending_flatStable0%
1
1
1
1
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 13 therapeutic areas and 15 of 98 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 86 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
27
Sponsors (total)
29
Active sponsors
22

Sponsor Network

Top 22 by active trials.

lock +21 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +6 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
42
Outperforms 82% of sites
public
Therapeutic diversity
14areas
Outperforms 88% of sites
groups
Sponsor diversity
29sponsors
Outperforms 82% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola

lock Showing 1 of 42 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 98 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Carboplatin4Unknown2018-07-312026-06-01

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.